Molecular Diagnosis & Therapy

, Volume 11, Issue 2, pp 79–82 | Cite as

Impact of Pharmacogenomics on Clinical Practice in Oncology

  • Sharon Marsh
Current Opinion


Multiple drug strategies for many cancer types are now readily available and there is a clear need for tools to inform decision making on therapy selection. Although there is still a long way to go before pharmacogenomics achieves the goal of individualized selection of cancer treatment, promising progress is being made. Genetic testing for thiopurine methyltransferase (TPMT) variant alleles in patients prior to mercaptopurine administration, and for UGT1A1*28 in patients prior to administration of irinotecan therapy, along with the instigation of genotype-guided clinical trials (e.g. TYMS) are important advances in cancer pharmacogenomics. Markers for the toxicity and efficacy of many oncology drugs remain unknown; however, the examples highlighted here suggest progress is being made towards the incorporation of pharmacogenomics into clinical practice in oncology.


Acute Lymphoblastic Leukemia Irinotecan Mercaptopurine TPMT Activity Frequent Variant Allele 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The author is supported by the National Institues of Health (grants UO1 GM63340 and R21 CA113491). The author has no conflicts of interest that are directly relevant to the content of this article.


  1. 1.
    Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005 Dec 20; 23(36): 9441–2PubMedCrossRefGoogle Scholar
  2. 2.
    Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006 Jan 12; 354(2): 166–78PubMedCrossRefGoogle Scholar
  3. 3.
    Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001 Feb 15; 409(6822): 928–33PubMedCrossRefGoogle Scholar
  4. 4.
    Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003 Feb 6; 348(6): 538–49PubMedCrossRefGoogle Scholar
  5. 5.
    Marsh S, McLeod HL. Cancer pharmacogenetics. Br J Cancer 2004 Jan 12; 90(1): 8–11PubMedCrossRefGoogle Scholar
  6. 6.
    Marsh S, McLeod HL. Pharmacogenomics: from bedside to clinical practice. Hum Mol Genet 2006 Apr 15; 15 (Spec. No. 1.): R89–93PubMedCrossRefGoogle Scholar
  7. 7.
    Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001 Feb 15; 409(6822): 860–921PubMedCrossRefGoogle Scholar
  8. 8.
    Wheeler DL, Barrett T, Benson DA, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2005 Jan 1; 33: D39–45PubMedCrossRefGoogle Scholar
  9. 9.
    The International HapMap Project. Nature 2003 Dec 18; 426 (6968): 789-96Google Scholar
  10. 10.
    Altshuler D, Brooks LD, Chakravarti A, et al. A haplotype map of the human genome. Nature 2005 Oct 27; 437(7063): 1299–320CrossRefGoogle Scholar
  11. 11.
    Syvanen AC. Toward genome-wide SNP genotyping. Nat Genet 2005 Jun; 37S: S5–10CrossRefGoogle Scholar
  12. 12.
    Freimuth RR, Ameyaw M-M, Pritchard SC, et al. High-throughput genotyping methods for pharmacogenomic studies. Curr Pharmacogenomics 2004; 2(1): 21–33CrossRefGoogle Scholar
  13. 13.
    Schrag D. The price tag on progress: chemotherapy for colorectal cancer. N Engl J Med 2004 Jul 22; 351(4): 317–9PubMedCrossRefGoogle Scholar
  14. 14.
    Relling MV, Hancock ML, Boyett JM, et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999 May 1; 93(9): 2817–23PubMedGoogle Scholar
  15. 15.
    McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus: implications for clinical pharmacogenomics. Pharmacogenomics 2002 Jan; 3(1): 89–98PubMedCrossRefGoogle Scholar
  16. 16.
    Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999 Dec 1; 91(23): 2001–8PubMedCrossRefGoogle Scholar
  17. 17.
    Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003 Mar 1; 21(5): 807–14PubMedCrossRefGoogle Scholar
  18. 18.
    Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998 Jul 7; 95(14): 8170–4PubMedCrossRefGoogle Scholar
  19. 19.
    Guillemette C, Millikan RC, Newman B, et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 2000 Feb 15; 60(4): 950–6PubMedGoogle Scholar
  20. 20.
    Hall D, Ybazeta G, Destro-Bisol G, et al. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 1999 Oct; 9(5): 591–9PubMedCrossRefGoogle Scholar
  21. 21.
    Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000 Dec 15; 60(24): 6921–6PubMedGoogle Scholar
  22. 22.
    Innocenti F, Ratain MJ. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Huntingt) 2003 May; 17(5 Suppl. 5): 52–5Google Scholar
  23. 23.
    Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999 May; 65(5): 576–82PubMedCrossRefGoogle Scholar
  24. 24.
    Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2(1): 43–7PubMedCrossRefGoogle Scholar
  25. 25.
    Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004 Apr 15; 22(8): 1382–8PubMedCrossRefGoogle Scholar
  26. 26.
    FDA clears Third Wave pharmacogenetic test. Pharmacogenomics 2005; 6 (7): 671-2Google Scholar
  27. 27.
    Innocenti F, Undevia SD, Rosner GL, et al. Irinotecan (CPT-11) pharmacokinetics (PK) and neutropenia: interaction among UGT1A1 and transporter genes [abstract]. Proc Am Soc Clin Oncol 2005; 23: 136sGoogle Scholar
  28. 28.
    Sai K, Saeki M, Saito Y, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004 Jun; 75(6): 501–15PubMedCrossRefGoogle Scholar
  29. 29.
    Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004 Oct; 5(7): 835–43PubMedCrossRefGoogle Scholar
  30. 30.
    de Jong FA, Scott-Horton TJ, Kroetz DL, et al. Irinotecan-induced diarrhea: functional significance of polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007 Jan; 81(1): 42–9PubMedCrossRefGoogle Scholar
  31. 31.
    Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995 Apr 1; 55(7): 1407–12PubMedGoogle Scholar
  32. 32.
    Leichman CG, Lenz HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997 Oct; 15(10): 3223–9PubMedGoogle Scholar
  33. 33.
    Marsh S. Thymidylate synthase pharmacogenetics. Invest New Drugs 2005 Dec; 23(6): 533–7PubMedCrossRefGoogle Scholar
  34. 34.
    Horie N, Aiba H, Oguro K, et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995 Jun; 20(3): 191–7PubMedCrossRefGoogle Scholar
  35. 35.
    Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003 Jun 1; 63(11): 2898–904PubMedGoogle Scholar
  36. 36.
    Ulrich CM, Bigler J, Velicer CM, et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000 Dec; 9(12): 1381–5PubMedGoogle Scholar
  37. 37.
    Marsh S, Ameyaw MM, Githang’a J, et al. Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat 2000 Dec; 16(6): 528PubMedCrossRefGoogle Scholar
  38. 38.
    Luo HR, Lu XM, Yao YG, et al. Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem Genet 2002 Feb; 40(1–2): 41–51PubMedCrossRefGoogle Scholar
  39. 39.
    Kawakami K, Omura K, Kanehira E, et al. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 1999 Jul–Aug; 19(4B): 3249–52PubMedGoogle Scholar
  40. 40.
    Marsh S, Collie-Duguid ES, Li T, et al. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999 Jun 15; 58(3): 310–2PubMedCrossRefGoogle Scholar
  41. 41.
    Marsh S, McLeod HL. Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer 2001 Nov; 1(3): 175–8; discussion 79-81PubMedCrossRefGoogle Scholar
  42. 42.
    Horie N, Takeishi K. Functional structure of the promoter region of the human thymidylate synthase gene and nuclear factors that regulate the expression of the gene. Nucleic Acids Symp Ser 1995; (34): 77-8Google Scholar
  43. 43.
    Villafranca E, Okruzhnov Y, Dominguez MA, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001 Mar 15; 19(6): 1779–86PubMedGoogle Scholar
  44. 44.
    Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1(1): 65–70PubMedCrossRefGoogle Scholar
  45. 45.
    Lecomte T, Ferraz JM, Zinzindohoue F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004 Sep 1; 10(17): 5880–8PubMedCrossRefGoogle Scholar
  46. 46.
    Iacopetta B, Grieu F, Joseph D, et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001 Sep 14; 85(6): 827–30PubMedCrossRefGoogle Scholar
  47. 47.
    McLeod HL, Tan B, Malyapa R, et al. Genotype-guided neoadjuvant therapy for rectal cancer [abstract]. Proc Am Soc Clin Oncol 2005; 23: 197Google Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Division of OncologyWashington University School of MedicineSt LouisUSA

Personalised recommendations